Harbor Capital Advisors Inc. Acquires New Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Harbor Capital Advisors Inc. purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 2,732 shares of the medical research company's stock, valued at approximately $482,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. American National Bank & Trust purchased a new position in shares of IQVIA in the first quarter valued at about $26,000. ST Germain D J Co. Inc. increased its position in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares during the period. GKV Capital Management Co. Inc. purchased a new position in shares of IQVIA in the fourth quarter valued at about $39,000. Lee Danner & Bass Inc. purchased a new position in shares of IQVIA in the fourth quarter valued at about $44,000. Finally, Zions Bancorporation N.A. increased its position in shares of IQVIA by 55.2% in the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after acquiring an additional 85 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on IQV. Redburn Partners set a $188.00 price objective on shares of IQVIA in a research report on Friday, May 23rd. UBS Group reduced their price target on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Truist Financial reduced their price target on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research report on Thursday, April 10th. Hsbc Global Res cut shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Finally, JPMorgan Chase & Co. reduced their price target on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $226.32.

IQVIA Stock Up 0.3%

Shares of NYSE IQV traded up $0.53 during midday trading on Wednesday, hitting $154.63. The stock had a trading volume of 1,667,170 shares, compared to its average volume of 1,628,016. The business's 50 day moving average is $147.79 and its 200-day moving average is $176.74. The company has a market cap of $26.75 billion, a P/E ratio of 21.07, a PEG ratio of 1.69 and a beta of 1.28. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88. The company has a quick ratio of 0.82, a current ratio of 0.82 and a debt-to-equity ratio of 2.19.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. The firm had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The business's revenue was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.54 earnings per share. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.